Galectin Therapeutics (GALT) Non-Current Assets (2010 - 2026)
Galectin Therapeutics (GALT) posted quarterly Non-Current Assets of $68000.0 for Q1 2026, down 72.02% year-over-year from $243000.0 in Q1 2025, and down 29.17% quarter-over-quarter from $96000.0 in Q4 2025.
Galectin Therapeutics (GALT) Non-Current Assets (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Non-Current Assets history runs 17 years deep, the most recent figure standing at $68000.0 for Q1 2026.
- In Q1 2026, Non-Current Assets fell 72.02% year-over-year to $68000.0; the TTM figure through Mar 2026 stood at $475000.0 (down 59.05% YoY), while the FY2025 annual figure was $96000.0, down 60.49% from the prior year.
- Non-Current Assets for Q1 2026 stood at $68000.0, down from $96000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $793000.0 in Q3 2022, with the low at $68000.0 in Q1 2026.
- The 5-year median for Non-Current Assets is $306000.0 (2024), against an average of $360470.6.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets soared 10371.43% in 2022, then plunged 72.02% in 2026.
- Galectin Therapeutics' Non-Current Assets stood at $733000.0 in 2022, then plunged by 33.15% to $490000.0 in 2023, then plunged by 50.41% to $243000.0 in 2024, then plunged by 60.49% to $96000.0 in 2025, then declined by 29.17% to $68000.0 in 2026.
- Business Quant data shows GALT's Non-Current Assets at $68000.0 in Q1 2026, $96000.0 in Q4 2025, and $136000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | 68,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68,000.00 |
| Dec 31, 2025 | 96,000.00 |
| Sep 30, 2025 | 136,000.00 |
| Jun 30, 2025 | 175,000.00 |
| Mar 31, 2025 | 243,000.00 |
| Dec 31, 2024 | 243,000.00 |
| Sep 30, 2024 | 306,000.00 |
| Jun 30, 2024 | 368,000.00 |
| Mar 31, 2024 | 430,000.00 |
| Dec 31, 2023 | 490,000.00 |
| Sep 30, 2023 | 552,000.00 |
| Jun 30, 2023 | 613,000.00 |
| Mar 31, 2023 | 673,000.00 |
| Dec 31, 2022 | 733,000.00 |
| Sep 30, 2022 | 793,000.00 |
| Jun 30, 2022 | 101,000.00 |
| Mar 31, 2022 | 108,000.00 |
| Dec 31, 2021 | 7,000.00 |
| Sep 30, 2021 | 40,000.00 |
| Jun 30, 2021 | 71,000.00 |